Pharma — September 2024
-
Tysk storbank øger Lundbecks kursmål med en femtedel https://proinvestor.com/investornyt/1209510/tysk-storbank-oger-lundbecks-kursmal-med-en-femtedel
-
Dansk industriproduktion tager stort hop i juli drevet af blandt andet medicinalsektorenhttps://proinvestor.com/investornyt/1210101/dansk-industriproduktion-tager-stort-hop-i-juli-drevet-af-blandt-andet-medicinalsektoren
-
Why Did Merck Stock Rise 65%? https://proinvestor.com/investornyt/1210999/why-did-merck-stock-rise-65
-
2 Unstoppable Healthcare Stocks to Buy Right Now for Less Than $200 https://proinvestor.com/investornyt/1213649/2-unstoppable-healthcare-stocks-to-buy-right-now-for-less-than-200
-
After Moderna's Shocking News, Is the Stock a Buy or a Sell? https://proinvestor.com/investornyt/1213629/after-modernas-shocking-news-is-the-stock-a-buy-or-a-sell
-
Is Pfizer Stock A Better Pick Over AbbVie? https://proinvestor.com/investornyt/1213943/is-pfizer-stock-a-better-pick-over-abbvie
-
Lundbeck-topchef er positivt overrasket over pipelinen - opkøb kun én af flere muligheder https://proinvestor.com/investornyt/1215191/lundbeck-topchef-er-positivt-overrasket-over-pipelinen-opkob-kun-en-af-flere-muligheder
-
ALK ser stort potentiale i markedet for peanutallergi https://proinvestor.com/investornyt/1215776/alk-ser-stort-potentiale-i-markedet-for-peanutallergi
-
ALK: Fortsat optismisme om at få husstøvmidevaccine til Kina trods udfordringer https://proinvestor.com/investornyt/1216268/alk-fortsat-optismisme-om-at-fa-husstovmidevaccine-til-kina-trods-udfordringer
-
J&J's Subsidiary Red River Talc Files For Chapter 11 Bankruptcy To Resolve Ovarian Cancer Claims https://proinvestor.com/investornyt/1216779/jampjs-subsidiary-red-river-talc-files-for-chapter-11-bankruptcy-to-resolve-ovarian-cancer-claims
-
Astrazeneca (AZN) Suffers a Larger Drop Than the General Market: Key Insights https://proinvestor.com/investornyt/1216766/astrazeneca-azn-suffers-a-larger-drop-than-the-general-market-key-insights
-
Is Johnson & Johnson Stock a Buy?https://proinvestor.com/investornyt/1216914/is-johnson-amp-johnson-stock-a-buy
-
FDA greenlights Sanofi's Sarclisa in frontline multiple myeloma https://firstwordpharma.com/story/5897967
-
Sanofi gears up to seek approval of BTK inhibitor tolebrutinib in MS https://firstwordpharma.com/story/5897608
-
Sanofi rykker tættere på at udskille forbrugerdivision: Banker er klar med milliarder https://proinvestor.com/investornyt/1217838/sanofi-rykker-taettere-pa-at-udskille-forbrugerdivision-banker-er-klar-med-milliarder
-
Lilly's Alzheimer's therapy Kisunla gains approval in Japan https://firstwordpharma.com/story/5898393
-
Lundbeck-topchef ser ikke patentudløb sende selskabet helt af sporet https://proinvestor.com/investornyt/1218939/lundbeck-topchef-ser-ikke-patentudlob-sende-selskabet-helt-af-sporet
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind